Leveraging recent advances in plasma biomarkers to optimize early proof of concept trials in Alzheimer's disease

Ähnliche Einträge

• Leveraging recent advances in biomarkers to optimize early phase drug development in Alzheimer's Disease
  von: Garrett B Duncan, et al.
  Veröffentlicht: (2025)
• Breaking down the influences of placebo progression and percent slowing on the observed treatment difference in Alzheimer’s Disease clinical trials for populations in different disease stages
  von: Caleb W Dayley, et al.
  Veröffentlicht: (2025)
• Reflection on Statistical Innovations in The Past 25 Years of Alzheimer’s Disease Research
  von: Craig Mallinckrodt, et al.
  Veröffentlicht: (2025)
• Time saved in activities of daily living and whole‐brain volume: Post hoc analysis of a randomized feasibility trial of gamma oscillation treatment in participants with mild or moderate Alzheimer's disease
  von: Ralph Kern, et al.
  Veröffentlicht: (2025)
• Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease
  von: Linda J. Van Eldik, et al.
  Veröffentlicht: (2024)